CG Oncology
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
400 Spectrum Center Dr Ste 2040, Irvine,...Phone Number
(949) 409-3700Website
www.cgoncology.comRevenue
$5.1 MillionStock Symbol
CGONIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. At CG Oncology, we see a world where urologic cancer patients can benefit from their innovative immunotherapies to live with dignity and have an enhanced quality of life.Explore more
CG Oncology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CG Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at CG Oncology
Click to see if CG Oncology had a recent Job posting/layoffs
Check if CG Oncology has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on CG Oncology recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once CG Oncology has new funding data
Check out if CG Oncology is spiking on competitors!
Website visits: Recent activity has been detected on your website
CG Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when CG Oncology launches new products
Recommended Actions
Reach out to Masked Content who joined CG Oncology as Masked Content
Find more new buyers
Compare Similar Companies to CG Oncology
Compare insights from companies similar to CG Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CG Oncology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CG Oncology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CG Oncology.
CG Oncology financials insights
Gather financial insights about CG Oncology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$13.6M
2015
Series B
$10M
2019
Series C
$22M
2020
Series D
$47M
2022
Series E
$120M
2023
Other Financing Round
$105M
2024
Stock Offering
$380M
CG Oncology Tech Stack
A closer look at the technologies used by CG Oncology
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
CG Oncology has acquired a fill and finish site, with ongoing efforts to upgrade the facility to meet CBER inspection readiness standards, including the engagement of ex-FDA inspectors on a contract basis to prepare for inspection. The site has previously been inspected by CDRH with no Form 483 observations cited.
Facilities Relocation/Expansion
Project
CG Oncology has reported a 92% complete response rate in evaluable patients from the CORE-008 cohort CX study evaluating cretostimogene in combination with gemcitabine in BCG-exposed patients, compared to a 76% complete response rate observed with cretostimogene monotherapy in the BOND-003 study. Updated 12-month data from this cohort is expected to be reported later in the year.
Project
CG Oncology has announced plans to hire a field force of 50 to 75 sales representatives to support its upcoming commercial launch, consistent with the competitive landscape given the concentration of target accounts.
Project
CG Oncology has reported that cretostimogene achieved a complete response (CR) rate of approximately 76% at any time in the BCG-unresponsive carcinoma in situ (CIS) cohort, with a 12-month landmark CR rate of 46% and a 24-month landmark CR rate of 42%, with the median duration of response not yet met but exceeding 25 months. Additional data beyond 24 months is expected to be reported later in the year as the study continues through three years of follow-up.
Project
CG Oncology News & Media
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York. Kuan said the company believes the therapy couCG Oncology to Present at Upcoming Investor Conferences in June
DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the recipients of the second annual CG-SUO-CTC NMIBC Research FCG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CG Oncology
Sign Up For FreeTo access detailed company insights
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. At CG Oncology, we see a world where urologic cancer patients can benefit from their innovative immunotherapies to live with dignity and have an enhance... Read More
